Overview

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the United Kingdom (UK), specializing in Hepatitis C treatment. The study is non-interventional and is designed to identify subgroups of Hepatitis C Virus (HCV) genotype 1 participants in the 'real world', including the relation between subgroup characteristics and treatment responsiveness.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Interferon-alpha
Peginterferon alfa-2b
Ribavirin